scholarly journals Study of the correlation between CA15-3 and each of prolactin hormone and lactate dehydrogenase enzyme in women with breast cancer in THI – QAR governorate – Iraq

2019 ◽  
Vol 10 (3) ◽  
pp. 1751-1755
Author(s):  
Hadeel Rashid Faraj

The most malicious tumor in women is breast cancer. Its treatment at the early stage of its recognition in a woman provides her multiple options for diagnosis. Physical inspection and mammography are helpful screening processes for the primary recognition of breast cancer, they are also labor dependent and need health specialists who are exceptionally prepared and skilled. This experiment was designed to estimate and compare the CA15-3 level, hormone, and Lactate dehydrogenase enzyme in Breast Cancer patients and in apparently healthier individuals. Blood CA15-3, hormone, and Lactate dehydrogenase enzyme levels were determined in 65 Women with Breast Cancer and 55 apparently healthy subjects. The levels of serum CA15-3, hormone, and Lactate dehydrogenase enzyme were showing a significant increase in women with Breast Cancer in comparison to the control group (P ≤ 0.05). The study also investigates the correlation between the concentrations of the CA15-3 and each of hormone, and Lactate dehydrogenase enzyme, However, we compared all measurement parameters according to the type of disease. In Breast cancer patients, we increase CA15-3, hormone, and Lactate dehydrogenase enzyme can clearly occur, and we positive correlation relationship between CA15-3 and each of PRL and LDH through coefficient correlation (r).

2008 ◽  
Vol 26 (26) ◽  
pp. 4289-4295 ◽  
Author(s):  
Tiina Saarto ◽  
Leena Vehmanen ◽  
Carl Blomqvist ◽  
Inkeri Elomaa

PurposeWe have previously reported that 3-year adjuvant clodronate treatment prevents bone loss in breast cancer patients. Here we report the 10-year follow-up data of clodronate in the prevention of treatment-related osteoporosis in women with early-stage breast cancer.Patients and MethodsTwo hundred sixty-eight pre- and postmenopausal, node-positive breast cancer patients were randomly assigned to clodronate, 1.6 g orally administered daily, or to control groups for 3 years. Premenopausal women were treated with adjuvant CMF chemotherapy; and postmenopausal women were treated with antiestrogens, either 20 mg tamoxifen or 60 mg toremifene, for 3 years. The bone mineral density (BMD) of the lumbar spine and hip was measured before treatment and at 1, 2, 3, 5, and 10 years after therapy.ResultsEighty-nine disease-free patients were included in the analyses of osteoporosis-free survival. During the 10-year period, 24 of 89 patients were diagnosed with osteoporosis. Fourteen patients developed spinal osteoporosis (three of 41 in the clodronate group, and 11 of 48 in the control group), and 14 of 89 patients were diagnosed with hip osteoporosis (seven of 41 in the clodronate group, and seven of 48 in the control group). The 10-year spinal, osteoporosis-free survival rate was 92.7% in the clodronate group, and 77.0% in the control group (P = .035). No difference was seen in the frequency of hip osteoporosis (85.4% v 82.9%; P = .92). Baseline BMD measurement had a predictive value of 18 of 24 patients (75%) who developed osteoporosis had osteopenia of the lumbar spine at baseline.ConclusionThree years of clodronate therapy significantly reduces the incidence of lumbar spine osteoporosis. Patients at risk of developing osteoporosis are among those who have pretreatment osteopenia, that is, baseline BMD measurement has predictive value.


2007 ◽  
Vol 125 (1) ◽  
pp. 22-28 ◽  
Author(s):  
Claudio Battaglini ◽  
Martim Bottaro ◽  
Carolyn Dennehy ◽  
Logan Rae ◽  
Edgar Shields ◽  
...  

CONTEXT AND OBJECTIVE: Changes in metabolism have been reported in the majority of patients undergoing cancer treatment, and these are usually characterized by progressive change in body composition. The effects of aerobic exercise programs to combat the cancer and cancer treatment-related side effects, which include the negative changes in body composition, have been extensively reported in the literature. However, few resistance exercise intervention studies have hypothesized that breast cancer patients might benefit from this type of exercise. The purpose of this study was to determine whether exercise protocols that emphasize resistance training would change body composition and strength in breast cancer patients undergoing treatment. DESIGN AND SETTING: Randomized controlled trial, at the Campus Recreation Center and Rocky Mountain Cancer Rehabilitation Institute of the University of Northern Colorado, and the North Colorado Medical Center. METHODS: Twenty inactive breast cancer patients were randomly assigned to a 21-week exercise group (n = 10) or a control group (n = 10). The exercise group trained at low to moderate intensity for 60 minutes on two days/week. The primary outcome measurements included body composition (skinfold method) and muscle strength (one repetition maximum). RESULTS: Significant differences in lean body mass, body fat and strength (p = 0.004, p = 0.004, p = 0.025, respectively) were observed between the groups at the end of the study. CONCLUSION: The results suggest that exercise emphasizing resistance training promotes positive changes in body composition and strength in breast cancer patients undergoing treatment.


2017 ◽  
Vol 78 ◽  
pp. 37-44 ◽  
Author(s):  
Ellen G. Engelhardt ◽  
Alexandra J. van den Broek ◽  
Sabine C. Linn ◽  
Gordon C. Wishart ◽  
Emiel J. Th. Rutgers ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document